South & Central America Branded Generics Market Forecast to 2028 – COVID

South & Central America Branded Generics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Therapeutic Application (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics and Anti-Inflammatory, and Others), Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies, and Drug Stores), Drug Class (Alkylating Agents, Antimetabolites, Hormones, Antihypertensive, Lipid-Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptic, and Others), and Formulation Type (Oral, Parenteral, Topical, and Others)

Report Code : BMIRE00026057 | Region : LAMEA | Industry : Pharmaceuticals | Published Date : 19/Sep/2022

The branded generics market in South & Central America is expected to grow from US$ 24.33 billion in 2022 to US$ 43.28 billion by 2028; it is estimated to grow at a CAGR of 10.1% from 2022 to 2028.

The branded generics market growth in South & Central America is attributed to the aging population, flourishing diagnostics market, and increasing initiatives by major players in the medical industry. Furthermore, the rising prevalence of chronic diseases that demand affordable therapeutic options is expected to provide opportunities to the market in this region during the forecast period. By country, the market in the rest of South & Central America is segmented into Chile, Colombia, Peru, Cuba, Venezuela, and Bolivia. These countries are investing significantly in improving healthcare services, focusing on primary and advanced care. According to data by World Bank, ~12% of the population in Chile was reported to be more than 65 years of age in 2020. With the increasing geriatric population, the prevalence of diabetes, cancer, and cardiovascular diseases is also on the rise, simultaneously driving developments in the pharmaceutical and healthcare industries in the rest of South & Central America. Therefore, the expected increase in the number of healthcare settings in these countries and the rise in the geriatric population are likely to provide significant opportunities for the growth of the branded generics market players in the coming years.

By introducing new features and technologies, vendors in the Europe branded generics market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market at a good CAGR during the forecast period.

outh & Central America Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)

South & Central America Branded Generics Market Segmentation

South & Central America branded generics market is segmented into therapeutic application, distribution channel, drug class, formulation type and country. The therapeutic application segment of the South & Central America branded generics market is segmented into oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, and analgesics and anti-inflammatory. In 2022, the others segment held the largest share of the market, by therapeutic application. The South & Central America branded generics market, by distribution channel is hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. The retail pharmacies segment is likely to hold the largest share of the market in 2022. The South & Central America branded generics market, by drug class is segmented into alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptic, and others. The others segment is likely to hold the largest share of the market in 2022. The South & Central America branded generics market, based on formulation type is segmented into oral, parenteral, topical, and other. In 2022, the oral segment held the largest share of the market, by formulation type. Based on country, the South & Central America branded generics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil held the largest market share in 2022.

Aspen Holdings, AstraZeneca, Bausch Health (Valeant Pharmaceuticals), Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Hetero, Lupin, Mylan N.V., Par Pharmaceuticals, Sandoz International Gmbh, Sanofi, and Teva Pharmaceutical Industries Ltd. are among the leading companies in the branded generics market operating in this region.

At 10.1% CAGR, the South & Central America Branded Generics Market is speculated to be worth US$ 43.28 Billion by 2028, says The Insight Partners

According to The Insight Partners’ research, the South & Central America branded generics market was valued at US$ 24.33 billion in 2022 and is expected to reach US$ 43.28 billion by 2028, registering an annual growth rate of 10.1% from 2022 to 2028. Product differentiation providing new opportunities and encouraging utility of branded generics by healthcare providers and professionals are the critical factors attributed to the market expansion.

The pharmaceutical industry is one of the most intensively regulated sectors, and as a result of these challenges, returns on R&D investment in the pharmaceutical industry have decreased. One feasible alternative for addressing such challenges is adopting strategies such as product differentiation to reduce development costs and maximize profits. Product differentiation deals with developing innovative products based on an existing product by creating better features, performance, or efficacy. Product differentiation paves the way for strengthening product pipeline and lifecycle management. As generic drugs contain the same active pharmaceutical ingredients as the brand-name product, differentiation in the color, shape, taste, inactive ingredients, preservatives, and packaging result in high demand for branded generics. Therefore, differentiation in the final product is expected to offer lucrative growth opportunities for the competitive players in the market.

Additionally, prominent players in the market are focusing on offering low-cost branded generics to remain competitive in the market. For instance, in July 2020, Takeda Pharmaceutical Company announced a joint venture with Teva Pharmaceuticals Industries Ltd., aiming to commercialize complex generics products, specialty assets, and other pipeline generic medicines. Further, key players in the branded generics segment focus on offering low-cost branded generics to remain competitive in the MEA market. This can be achieved by strategically sourcing raw materials from emerging economies and partnering with suppliers. All these factors may provide lucrative opportunities for the overall branded generics market growth during the forecast period.

On the contrary, switching brands, poorer clinical outcomes and adverse effects of generic medications hurdles the growth of South & Central America branded generics market.

The therapeutic application segment of the South & Central America branded generics market is segmented into oncology, cardiovascular diseases, diabetes, neurology, gastrointestinal diseases, dermatology diseases, and analgesics and anti-inflammatory. With 30.4% market share the others segment held the largest share of the market in 2022 amassing to US$ 7.40 billion. It is projected to garner US$ 12.99 billion by 2028 to expand at 9.8% CAGR during 2022–2028.

Based on distribution channel, the branded generics market sphere is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and drug stores. The retail pharmacies held 58.0% market share in 2022, amassing US$ 14.11 billion. It is projected to garner US$ 25.10 billion by 2028 to expand at 10.1% CAGR during 2022–2028.

The South & Central America branded generics market, by drug class is segmented into alkylating agents, antimetabolites, hormones, anti-hypertensive, lipid lowering drugs, anti-depressants, anti-psychotics, anti-epileptic, and others. With 70.4% share of the domain, the others segment dominated the market in 2022. It held US$ 17.13 billion in 2022 and is estimated to generate US$ 30.39 billion by 2028 to grow at a CAGR of 10.0% over the forecast period.

The South & Central America branded generics market, based on formulation type is segmented into oral, parenteral, topical, and others. With 57.8% share of the domain, the oral segment dominated the market in 2022. It accrued US$ 14.05 billion in 2022 and is estimated to generate US$ 24.95 billion by 2028 to grow at a CAGR of 10.0% over the forecast period.

Our regional analysis states that the Brazil captured 54.5% market share in 2022. It was assessed at US$ 13.26 billion in 2022 and is likely to hit US$ 24.17 billion by 2028, exhibiting a CAGR of 10.5% during the forecast period.

Key players dominating the South & Central America branded generics market are Aspen Holdings, AstraZeneca, Bausch Health (Valeant Pharmaceuticals), Dr. Reddy's Laboratories Inc., GlaxoSmithKline plc, Hetero, Lupin, Mylan N.V., Par Pharmaceuticals, Sandoz International Gmbh, Sanofi, and Teva Pharmaceutical Industries Ltd. among others.

TABLE OF CONTENTS

1. Introduction

1.1 Study Scope

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 SAM Branded Generics Market – By Therapeutic Application

1.3.2 SAM Branded Generics Market – By Distribution Channel

1.3.3 SAM Branded Generics Market – By Drug Class

1.3.4 SAM Branded Generics Market – By Formulation Type

1.3.5 SAM Branded Generics Market – By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. SAM Branded Generics Market – Market Landscape

4.1 Overview

4.2 SAM PEST Analysis

4.3 Experts Opinion

5. SAM Branded Generics Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Penetration of Branded Generics

5.2 Market Restraints

5.2.1 Switching Brands, Poorer Clinical Outcomes and Adverse Effects of Generic Medications

5.3 Market Opportunities

5.3.1 Product Differentiation

5.4 Future Trends

5.4.1 Encouraging Utility of Branded Generics by Healthcare Providers and Professionals

5.5 Impact Analysis

6. Branded Generics Market– SAM Analysis

6.1 SAM Branded Generics Market Revenue Forecast and Analysis

6.2 SAM Branded Generics Market, By Country - Forecast and Analysis

7. SAM Branded Generics Market Revenue and Forecast To 2028– by Therapeutic Application

7.1 Overview

7.2 SAM Branded Generics Market Revenue Share, By Therapeutic Application: Market Revenue and Forecast Analysis (US$ Billion)

7.3 Oncology

7.3.1 Overview

7.3.2 Oncology Market Revenue and Forecast to 2028 (US$ Billion)

7.4 Cardiovascular Diseases

7.4.1 Overview

7.4.2 Cardiovascular Diseases Market Revenue and Forecast to 2028 (US$ Billion)

7.5 Diabetes

7.5.1 Overview

7.5.2 Diabetes Market Revenue and Forecast to 2028 (US$ Billion)

7.6 Neurology

7.6.1 Overview

7.6.2 Neurology Market Revenue and Forecast to 2028 (US$ Billion)

7.7 Gastrointestinal Diseases

7.7.1 Overview

7.7.2 Gastrointestinal Diseases Market Revenue and Forecast to 2028 (US$ Billion)

7.8 Dermatology Diseases

7.8.1 Overview

7.8.2 Dermatology Diseases Market Revenue and Forecast to 2028 (US$ Billion)

7.9 Analgesics and Anti-Inflammatory

7.9.1 Overview

7.9.2 Analgesics and Anti-Inflammatory Market Revenue and Forecast to 2028 (US$ Billion)

7.10 Others

7.10.1 Overview

7.10.2 Others Market Revenue and Forecast to 2028 (US$ Billion)

8. SAM Branded Generics Market Analysis and Forecast to 2028 by Distribution Channel

8.1 SAM Branded Generics Market Revenue Share, by Distribution Channel (2022 and 2028)

8.2 Hospital Pharmacies

8.2.1 Overview

8.2.2 Hospital Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

8.3 Retail Pharmacies

8.3.1 Overview

8.3.2 Retail Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

8.4 Online Pharmacies

8.4.1 Overview

8.4.2 Online Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

8.5 Drug Stores

8.5.1 Overview

8.5.2 Drug Stores: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9. SAM Branded Generics Market Analysis and Forecast to 2028 by Drug Class

9.1 SAM Branded Generics Market Revenue Share, by Drug Class (2022 and 2028)

9.2 Alkylating Agents

9.2.1 Overview

9.2.2 Alkylating Agents: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.3 Antimetabolites

9.3.1 Overview

9.3.2 Antimetabolites: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.4 Hormones

9.4.1 Overview

9.4.2 Hormones: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.5 Anti-hypertensive

9.5.1 Overview

9.5.2 Anti-hypertensive: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.6 Lipid Lowering Drugs

9.6.1 Overview

9.6.2 Lipid Lowering Drugs: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.7 Anti-Depressants

9.7.1 Overview

9.7.2 Anti-Depressants: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.8 Anti-psychotics

9.8.1 Overview

9.8.2 Anti-psychotics: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.9 Anti-epileptic

9.9.1 Overview

9.9.2 Anti-epileptic: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

9.10 Others

9.10.1 Overview

9.10.2 Others: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

10. SAM Branded Generics Market Analysis and Forecast to 2028 – by Formulation Type

10.1 Overview

10.2 SAM Branded Generics Market Revenue Share, by Formulation Type (2022 and 2028)

10.3 Oral

10.3.1 Overview

10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Billion)

10.4 Parenteral

10.4.1 Overview

10.4.2 Parenteral Market Revenue and Forecast to 2028 (US$ Billion)

10.5 Topical

10.5.1 Overview

10.5.2 Topical Market Revenue and Forecast to 2028 (US$ Billion)

10.6 Others

10.6.1 Overview

10.6.2 Others Market Revenue and Forecast to 2028 (US$ Billion)

11. SAM Branded Generics Market Revenue and Forecasts to 2028 Country Analysis

11.1 Overview

11.1.1 SAM: Branded Generics Market Revenue and Forecasts to 2028, By Country (%)

11.1.1.1 Argentina Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)

11.1.1.1.1 Overview

11.1.1.1.2 Argentina: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)

11.1.1.1.3 Argentina: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)

11.1.1.1.4 Argentina: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)

11.1.1.1.5 Argentina: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)

11.1.1.1.6 Argentina: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)

11.1.1.2 Brazil: Branded Generics Market Revenue and Forecast to 2028 (US$ Billion)

11.1.1.2.1 Overview

11.1.1.2.2 Brazil: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)

11.1.1.2.3 Brazil: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)

11.1.1.2.4 Brazil: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)

11.1.1.2.5 Brazil: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)

11.1.1.2.6 Brazil: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)

11.1.1.3 Rest of South and Central America: Branded Generics Market– Revenue and Forecast to 2028 (USD Billion)

11.1.1.3.1 Overview

11.1.1.3.2 Rest of SAM: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)

11.1.1.3.3 Rest of SAM: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)

11.1.1.3.4 Rest of SAM: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)

11.1.1.3.5 Rest of SAM: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)

11.1.1.3.6 Rest of SAM: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)

12. Branded Generics Market–Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

13.1 MYLAN N.V.

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 TEVA PHARMACEUTICAL INDUSTRIES LTD

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 GlaxoSmithKline plc.

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Bausch Health Companies Inc.

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Lupin

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Sanofi

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 ASTRAZENECA PLC.

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Dr. Reddy's Laboratories

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 Par Pharmaceuticals, INC

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Sandoz International GMBH

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

13.11 Aspen Holdings

13.11.1 Key Facts

13.11.2 Business Description

13.11.3 Products and Services

13.11.4 Financial Overview

13.11.5 SWOT Analysis

13.11.6 Key Developments

13.12 Hetero

13.12.1 Key Facts

13.12.2 Business Description

13.12.3 Products and Services

13.12.4 Financial Overview

13.12.5 SWOT Analysis

13.12.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES.

Table 1.             Argentina: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)

Table 2.             Argentina: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)

Table 3.             Argentina: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)

Table 4.             Argentina: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)

Table 5.             Brazil: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)

Table 6.             Brazil: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)

Table 7.             Brazil: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)

Table 8.             Brazil: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)

Table 9.             Rest of SAM: Branded Generics Market Revenue and Forecasts to 2028, By Therapeutic Application (US$ Billion)

Table 10.          Rest of SAM: Branded Generics Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Billion)

Table 11.          Rest of SAM: Branded Generics Market, by Drug Class – Revenue and Forecast to 2028 (US$ Billion)

Table 12.          Rest of SAM: Branded Generics Market, by Formulation Type– Revenue and Forecast to 2028 (US$ Billion)

Table 13.          Organic Developments Done By Companies

Table 14.          Inorganic Developments Done By Companies

Table 15.          Glossary of Terms

LIST OF FIGURES.

Figure 1.           SAM Branded Generics Market Segmentation

Figure 2.           SAM Branded Generics Market, By Country

Figure 3.           SAM Branded Generics Market Overview

Figure 4.           Others Segment Held Largest Share of Drug Class Segment in SAM Branded Generics Market

Figure 5.           Brazil is Expected to Show Remarkable Growth During the Forecast Period

Figure 6.           SAM: PEST Analysis

Figure 7.           Experts Opinion

Figure 8.           Impact Analysis of Drivers and Restraints on SAM Branded Generics Market

Figure 9.           SAM Branded Generics Market – By Country Forecast and Analysis – 2019 - 2028

Figure 10.        SAM Branded Generics Market Revenue Share, By Therapeutic Application: Market Analysis and Forecast 2022 and 2028 (%)

Figure 11.        SAM Oncology Market Revenue and Forecast to 2028 (US$ Billion)

Figure 12.        SAM Cardiovascular Diseases Market Revenue and Forecast to 2028 (US$ Billion)

Figure 13.        SAM Diabetes Market Revenue and Forecast to 2028 (US$ Billion)

Figure 14.        SAM Neurology Market Revenue and Forecast to 2028 (US$ Billion)

Figure 15.        SAM Gastrointestinal Diseases Market Revenue and Forecast to 2028 (US$ Billion)

Figure 16.        SAM Dermatology Diseases Market Revenue and Forecast to 2028 (US$ Billion)

Figure 17.        SAM Analgesics and Anti-Inflammatory Market Revenue and Forecast to 2028 (US$ Billion)

Figure 18.        SAM Others Market Revenue and Forecast to 2028 (US$ Billion)

Figure 19.        SAM Branded Generics Market Revenue Share, by Distribution Channel (2022 and 2028)

Figure 20.        SAM Hospital Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 21.        SAM Retail Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 22.        SAM Online Pharmacies: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 23.        SAM Drug Stores: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 24.        SAM Branded Generics Market Revenue Share, by Drug Class (2022 and 2028)

Figure 25.        SAM Alkylating Agents: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 26.        SAM Antimetabolites: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 27.        SAM Hormones: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 28.        SAM Anti-hypertensive: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 29.        SAM Lipid Lowering Drugs: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 30.        SAM Anti-Depressants: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 31.        SAM Anti-psychotics: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 32.        SAM Anti-epileptic: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 33.        SAM Others: Branded Generics Market – Revenue and Forecast to 2028 (US$ Billion)

Figure 34.        SAM Branded Generics Market Revenue Share, by Formulation Type (2022 and 2028)

Figure 35.        SAM Oral Market Revenue and Forecast to 2028 (US$ Billion)

Figure 36.        SAM Parenteral Market Revenue and Forecast to 2028 (US$ Billion)

Figure 37.        SAM Topical Market Revenue and Forecast to 2028 (US$ Billion)

Figure 38.        SAM Others Market Revenue and Forecast to 2028 (US$ Billion)

Figure 39.        SAM Branded Generics Market Overview, by Country (2022)

Figure 40.        SAM: Branded Generics Market Revenue and Forecasts to 2028, By Country (%)

Figure 41.        Argentina: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)

Figure 42.        Brazil: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)

Figure 43.        Rest of SAM: Branded Generics Market Revenue and Forecasts to 2028 (US$ Billion)

Figure 44.        Growth Strategies Done by the Companies in the Market (%)

The List of Companies - South & Central America Branded Generics Market

● Aspen Holdings

● AstraZeneca

● Bausch Health (Valeant Pharmaceuticals)

● Dr. Reddy's Laboratories Inc.

● GlaxoSmithKline plc

● Hetero

● Lupin

● Mylan N.V.

● Par Pharmaceuticals

● Sandoz International Gmbh

● Sanofi

● Teva Pharmaceutical Industries Ltd.

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South & Central America branded generics market

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the South & Central America branded generics market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the branded generics market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

TOP